Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
- ILLUMINATE-B Workgroup
- Mayo Clinic Rochester, MN
- Rambam Health Care Campus Israel
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Western Galilee Medical Center of Nahariya
- Texas Children's Hospital Houston
- University of Bonn
- Hospices civils de Lyon
- Alnylam Pharmaceuticals
- Shaare Zedek Medical Center
- Hebrew University of Jerusalem
Research output: Contribution to journal › Article › peer-review
64
Scopus
citations